{
    "body": "What alternate indication has Vanoxerine been repositioned for?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/21615815", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27108936", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19817928", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19817929", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25684233", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26616666"
    ], 
    "triples": [
        {
            "p": "http://www.w3.org/2000/01/rdf-schema#label", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0164200", 
            "o": "vanoxerine"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0164200", 
            "o": "http://linkedlifedata.com/resource/umls/label/A17685361"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A17685361", 
            "o": "VANOXERINE"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#prefLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0164200", 
            "o": "http://linkedlifedata.com/resource/umls/label/A0294723"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A0294723", 
            "o": "vanoxerine"
        }, 
        {
            "p": "http://www.w3.org/2000/01/rdf-schema#label", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0556030", 
            "o": "repositioning"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#altLabel", 
            "s": "http://linkedlifedata.com/resource/umls/id/C0556030", 
            "o": "http://linkedlifedata.com/resource/umls/label/A15558315"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A15558315", 
            "o": "Repositioned"
        }
    ], 
    "ideal_answer": [
        "Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter. Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy.", 
        "Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy. Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter. ", 
        "Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction and can potential treat atrial fibrillation", 
        "Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy. Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", 
        "vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", 
        "Vanoxerine 's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", 
        "vanoxerine's were strongly frequency-dependent and repositioned it for treatment of atrial fibrillation and flutter. . has been in clinical trials for parkinsonism , depression and cocaine addiction but lacked efficacy. . "
    ], 
    "exact_answer": [
        "atrial fibrillation and flutter"
    ], 
    "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056687", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4001200", 
        "http://www.biosemantics.org/jochem#4001200", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4258722", 
        "http://www.biosemantics.org/jochem#4151584", 
        "http://www.biosemantics.org/jochem#4258722", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4151584", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001145"
    ], 
    "type": "factoid", 
    "id": "58c9a8fe02b8c6095300002a", 
    "snippets": [
        {
            "offsetInBeginSection": 272, 
            "offsetInEndSection": 399, 
            "text": "Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616666", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 55, 
            "text": "Vanoxerine: cellular mechanism of a new antiarrhythmic.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817928", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 231, 
            "offsetInEndSection": 294, 
            "text": "Therefore, we proposed that vanoxerine might be antiarrhythmic.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817929", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 68, 
            "text": "Vanoxerine is a promising, new, investigational antiarrhythmic drug.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615815", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 85, 
            "text": "Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615815", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 269, 
            "offsetInEndSection": 396, 
            "text": "Vanoxerine's effects were strongly frequency-dependent and we repositioned it for treatment of atrial fibrillation and flutter.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26616666", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 245, 
            "offsetInEndSection": 308, 
            "text": "Therefore, we proposed that vanoxerine might be antiarrhythmic.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817929", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1592, 
            "offsetInEndSection": 1674, 
            "text": "Vanoxerine has characteristics of a potentially effective and safe antiarrhythmic.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817928", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 80, 
            "text": "BACKGROUND: Vanoxerine is a promising, new, investigational antiarrhythmic drug.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615815", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 86, 
            "text": "Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21615815", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 72, 
            "text": "Vanoxerine, a new drug for terminating atrial fibrillation and flutter.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19817929", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 164, 
            "text": "Vanoxerine is an oral, 1,4-dialkylpiperazine derivative antiarrhythmic drug being evaluated for pharmacological cardioversion of atrial fibrillation (AF", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27108936", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1420, 
            "offsetInEndSection": 1535, 
            "text": "Oral vanoxerine converted AF/AFL to SR at a high rate, was well tolerated, and caused no ventricular proarrhythmia.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25684233", 
            "endSection": "abstract"
        }
    ]
}